Drugs / HerpV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01687595 | Oct 2012 → Sep 2013 | genital herpes simplex type 2 infectious disorder | Agenus Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HerpV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01687595 ↗ |
| Modality | Vaccine | “HerpV vaccine” NCT01687595 ↗ |
| Route | Subcutaneous | “Participants will receive a combination of HerpV 240 micrograms (μg) and QS-21 50 μg injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1.” NCT01687595 ↗ |